Indefinite Delivery Contract SPE2DR25D9242

The Defense Logistics Agency (DLA) has awarded a single-award Indefinite Delivery Contract (IDC) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, to provide a comprehensive range of pharmaceutical products and medical supplies to the Department of Defense (DoD) and other government agencies. The contract, valued at $499,999,999, is valid through November 2026 and covers an extensive portfolio of branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables. This IDC enables the DLA to issue firm fixed-price delivery orders to support the recurring medical supply needs of military healthcare facilities and veterans' medical centers nationwide.

The DLA is also planning to issue a solicitation for the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) to establish multiple regional contracts for worldwide pharmaceutical support to various DoD customers. The anticipated $30.3 billion contract will have a 30-month base period and three 30-month option periods, with awards made to the responsive and responsible offerors whose proposals are technically acceptable and offer the lowest overall distribution fees. The solicitation is expected to be issued in March 2024 and remain open for 45 days, with no set-aside designations. The DLA intends to make at least three separate regional awards to ensure diversification and resiliency in the federal pharmaceutical supply chain.